In odd aftermath of FDA Commissioner Mark McClellan’s lecture, NCI Director Andrew von Eschenbach forwards the commissioner’s thank-you note to 3,000 NCI staff. The email blast follows FDA’s return of NCI’s gift to McClellan.
Also in this 8-page issue: NCI informatics project caBIG will “rapidly accelerate” cancer research, von Eschenbach says.
NCI plans 18 percent budget cuts for large R01s, smaller cuts to other research project grants. NCI treatment division director Ellen Feigal accepts position with Translational Genomics Research Institute in Phoeniz, Ariz.
In the cancer centers: San Antonio Cancer Institute gets a new director, funding commitments.
UT Health Science Center dedicates new Children’s Cancer Research Institute.
Funding opportunities listed.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns
